Endocrine Society Guidelines on Central Precocious Puberty
The 2026 Endocrine Society guidelines recommend GnRH agonist treatment for many children with central precocious puberty (CPP), but emphasize a more selective diagnostic and therapeutic approach than traditional practice, particularly for girls aged 7-8 years with slowly progressive puberty who may not require immediate intervention. 1
Definition and Diagnostic Criteria
CPP is defined as secondary sexual characteristics appearing before:
- Age 8 years in girls (Tanner stage B2 breast development)
- Age 9 years in boys (testicular volume ≥4 mL)
This represents premature activation of the hypothalamic-pituitary-gonadal axis 1, 2.
Key Diagnostic Recommendations
Initial Evaluation Strategy
For girls with breast development between ages 7.0-8.0 years, the guidelines suggest watchful waiting with periodic physical examinations every 4-6 months rather than immediate laboratory or imaging evaluation. 1 This represents a significant departure from traditional practice and is based on evidence that girls with slowly progressive puberty attain normal adult height without treatment.
All girls with breast development before age 7 years should be observed for 4-6 months first to differentiate unsustained or slowly progressive puberty from rapidly progressive puberty before initiating full diagnostic workup 1.
Hormonal Testing
When hormonal confirmation is needed:
- Start with ultrasensitive basal LH concentration rather than routine GnRH/GnRHa stimulation testing for all patients 1
- This streamlined approach reduces unnecessary invasive testing while maintaining diagnostic accuracy
Brain Imaging
Brain MRI should NOT be routinely performed in:
- Girls ages 6.0-8.0 years without CNS symptoms
- Boys ages 8.0-9.0 years without CNS symptoms
This recommendation is based on low prevalence (6%) of pathologic intracranial findings in these age groups 1, 3. However, MRI remains indicated for:
- Children with neuro-ophthalmologic symptoms
- Boys younger than 8 years (higher risk of pathology)
- Girls younger than 6 years
Genetic Testing
The guidelines suggest against routine genetic testing for CPP patients. However, genetic testing (particularly MKRN3 sequencing) should be considered through shared decision-making for patients with familial CPP 1.
Treatment Recommendations
GnRH Agonist Therapy
GnRHa treatment is suggested for many children with CPP, with the understanding that certain subgroups may be less likely to benefit:
- Older girls (7-8 years) with slowly progressive CPP may not require treatment
- Treatment provides approximately +2.7 cm adult height gain in girls with idiopathic CPP 3
Treatment Initiation
Start with the long-acting GnRHa formulation anticipated for long-term use rather than defaulting to monthly injectable formulations 1. This improves adherence and reduces treatment burden.
Available GnRHa options include:
- Monthly depot injections
- 3-month depot formulations
- 6-month depot formulations
- Annual subcutaneous implants
Monitoring During Treatment
The guidelines suggest against routine biochemical testing (LH, sex steroids) to monitor pubertal suppression while receiving GnRHa 1. Instead:
- Reserve biochemical testing for clinically suspected treatment failure
- Monitor primarily through physical examination (Tanner staging)
- Assess growth velocity and bone age progression
Growth Hormone Co-treatment
The guidelines suggest against routine addition of growth hormone therapy to increase adult height in children with CPP receiving GnRHa 1. GH should only be considered if true GH deficiency is documented.
Treatment Discontinuation
GnRHa treatment should NOT routinely continue beyond:
- Chronologic age 10.0-11.0 years in girls or 11.0-12.0 years in boys
- Bone age 11.0-12.0 years in girls or 12.0-13.0 years in boys
Continuing treatment beyond these ages provides minimal additional height benefit and delays normal pubertal development unnecessarily.
Important Clinical Nuances
Slowly vs Rapidly Progressive CPP
The guidelines emphasize differentiating these patterns, as slowly progressive CPP (particularly in older girls) may not require treatment. Key distinguishing features:
Rapidly progressive CPP:
- Bone age advancement >1 year beyond chronologic age
- Growth velocity >2 SD above mean for age
- Rapid Tanner stage progression
Slowly progressive CPP:
- Minimal bone age advancement
- Normal growth velocity
- Slow Tanner stage progression over 6-12 months
Special Populations
For childhood cancer survivors with CPP (particularly those with history of cranial radiation), treatment with GnRHa appears beneficial, especially when combined with GH therapy for those with concurrent GH deficiency 4. These patients may experience particularly poor adult height outcomes without intervention.
Common Pitfalls to Avoid
- Over-testing girls aged 7-8 years: Many will have slowly progressive puberty not requiring intervention
- Routine MRI in older children without symptoms: Low yield and unnecessary cost/anxiety
- Starting monthly injections by default: Consider patient preference and adherence with longer-acting formulations
- Routine biochemical monitoring: Clinical assessment is usually sufficient
- Continuing treatment too long: Stopping at appropriate chronologic/bone age prevents unnecessary pubertal delay
Evidence Quality Considerations
The 2026 guidelines 1 represent the most current Endocrine Society recommendations and supersede older guidance. The systematic review supporting these guidelines 3 identified significant evidence gaps, particularly regarding optimal timing of treatment discontinuation and identification of which patients truly benefit from intervention. The recommendations balance available evidence with practical clinical considerations including cost, feasibility, and patient values.
The shift toward more selective evaluation and treatment reflects evolving understanding that not all children meeting traditional CPP criteria require aggressive intervention, particularly girls in the 7-8 year age range with slowly progressive puberty who achieve normal adult height without treatment.